Day 2 - Wednesday 30th April 2025
12th Market Access, Pricing & Reimbursement Global Congress 2025 Europe
Comprehensive Strategies and Embracing Innovations to Overcome Barriers in Patient Access
Tuesday 29th - Wednesday 30th April 2025
Copthorne Tara Hotel London Kensington, London, UK
Josie Godfrey, Co-Founder and CEO, Realise Advocacy
PRICING & REIMBURSEMENT
- Challenges in drug pricing and reimbursement
- How to navigate a complex balance between financial and strategic risks
- Strategies to offset regulatory and inflationary pressures.
- Addressing environmental, social, and corporate governance issues
- Encouraging cross-functional or cross-company collaborations
- Increasing trends of using RWE in clinical development, regulatory and reimbursement decisions
- Integrating real-world data into early clinical development, regulatory and market access strategy (pricing and reimbursement)
- Significant role of RWE in value-based assessment & patient focused drug development
- Importance of developing a value-based market access and reimbursement strategy
- User cases of successful market access strategies with value evidence
Boxiong Tang, AVP, Head of HEOR & Medical Value Access, agenus inc
- The EU pricing stage : lessons from payers’ pricing negotiations
- Pricing confidentiality
- External Reference pricing
- Pricing and HTA methodology
Vasiliki Patsioura, Global Pricing Implementation Lead, AstraZeneca
- Effective communications with internal and external stakeholders
- Importance of stakeholder collaboration
- Understanding the benefits of a good collaboration between payers and pharma to ensure appropriate patient access
Marta Contente, Senior Director, Pipeline Head of Immunology, GHEVO, Teva
- Keeping on top of pricing and market access trends
- Identify a clinical or economic advantage and generate the appropriate clinical and health economic evidence to support a strong value proposition
- Optimising the use of Patient-Reported Outcomes
- Unlocking data from early access
- Effective communications with internal and external stakeholders
- Embracing the digital vision
- Advantages of market access teams in payer relationship
- Payer evidence requirement in early development
- Best practices to obtain better pricing and reimbursement
- Strategies to improve a better payer relationship
Alexander Bastian, VP, Commercial & Value Strategy, Memo Therapeutics AG
- Objective: Activating the full stakeholder ecosystem to shift conversation from price to value to get access to innovative therapies
- Why is the full stakeholder ecosystem important for gaining access in the future?
- How to Identify the stakeholder ecosystem for access success
- Step by step: Setting up a cross-functional program for access success
Catherine Akesson, Senior Consultant, Strategic Market Access, Congentia
2:30 pm - PLENARY SESSION: The impact of pharmaceutical tendering on prices and market concentration
- Assessment of financial benefit from tendering
- Evaluating its impact on prices and market concentration
- Consideration of its operational framework
- Tendering for pharmaceuticals as a reimbursement tool
- Why and how enterprises should invest into early HEOR and pathway improvement?
- How AI can impact early HEOR and pathway improvement evaluations: key benefits to the life sciences and medtech industry
- Case examples from the UK
- As innovation brings cancer drugs & curative medicines to the forefront of healthcare systems, how are payers affording to pay for this innovation ?
what are the new determinants of value in healthcare, and the geopolitical drivers for value based agreements & innovative contracting ? - If the drugs don’t work – I want my money back! – access into a global tracker of over 700 innovative contracts from around the globe
- Who’s shifting the paradigm – adoption curves for those manufacturers leading the way in capabilities
for innovative contracting
Moderator: Catherine Akesson, Senior Consultant, Strategic Market Access, Congentia
Panellists:
- The importance of making MA the core of the company
- Bridge between pre-launch strategy and post-launch
- Increasing collaboration between EU countries
- Frontiers in Health Care
- What will the future bring?
Moderator:
Panelists:
